Last reviewed · How we verify
metronidazole based quadriple therapy
Metronidazole-based quadruple therapy combines metronidazole with three other agents (typically a proton pump inhibitor, bismuth compound, and tetracycline or clarithromycin) to eradicate Helicobacter pylori through multiple antimicrobial and acid-suppressive mechanisms.
Metronidazole-based quadruple therapy combines metronidazole with three other agents (typically a proton pump inhibitor, bismuth compound, and tetracycline or clarithromycin) to eradicate Helicobacter pylori through multiple antimicrobial and acid-suppressive mechanisms. Used for Helicobacter pylori infection eradication in peptic ulcer disease, H. pylori-associated chronic gastritis.
At a glance
| Generic name | metronidazole based quadriple therapy |
|---|---|
| Also known as | concomitant quadruple therapy (QC) |
| Sponsor | mohamed bouchoucha |
| Drug class | Antibiotic combination therapy |
| Target | Helicobacter pylori DNA and bacterial cell integrity |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Metronidazole acts as a nitroimidazole antimicrobial that disrupts bacterial DNA in H. pylori. The quadruple regimen enhances efficacy by combining metronidazole's bactericidal activity with a proton pump inhibitor to reduce gastric acid (creating optimal conditions for drug activity), a bismuth compound for additional antimicrobial and mucosal protective effects, and a second antibiotic to overcome resistance and improve eradication rates. This multi-drug approach targets H. pylori through synergistic mechanisms.
Approved indications
- Helicobacter pylori infection eradication in peptic ulcer disease
- H. pylori-associated chronic gastritis
Common side effects
- Metallic taste
- Nausea
- Diarrhea
- Abdominal discomfort
- Headache
- Dark stool (from bismuth)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- metronidazole based quadriple therapy CI brief — competitive landscape report
- metronidazole based quadriple therapy updates RSS · CI watch RSS
- mohamed bouchoucha portfolio CI